CNBX Pharmaceuticals (CNBX) Retained Earnings (2016 - 2025)
CNBX Pharmaceuticals (CNBX) has disclosed Retained Earnings for 14 consecutive years, with -$25.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 1.57% year-over-year to -$25.4 million, compared with a TTM value of -$25.4 million through Nov 2025, down 1.57%, and an annual FY2025 reading of -$25.3 million, down 1.26% over the prior year.
- Retained Earnings was -$25.4 million for Q4 2025 at CNBX Pharmaceuticals, roughly flat from -$25.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$39191.0 in Q1 2021 and bottomed at -$25.4 million in Q4 2025.
- Average Retained Earnings over 5 years is -$19.6 million, with a median of -$23.7 million recorded in 2023.
- Peak annual rise in Retained Earnings hit 98.62% in 2021, while the deepest fall reached 9252.39% in 2021.
- Year by year, Retained Earnings stood at -$18.1 million in 2021, then fell by 15.2% to -$20.9 million in 2022, then dropped by 16.89% to -$24.4 million in 2023, then decreased by 2.25% to -$25.0 million in 2024, then fell by 1.57% to -$25.4 million in 2025.
- Business Quant data shows Retained Earnings for CNBX at -$25.4 million in Q4 2025, -$25.3 million in Q3 2025, and -$25.1 million in Q2 2025.